Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer door Nicole A. Traphagen (16677391)

Onderwerpen:

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer door Nicole A. Traphagen (16677391)

Onderwerpen:

Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis door Santanu Ghosh (16714626)

Onderwerpen:

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance door Marta J. Llorca-Cardenosa (14961612)

Onderwerpen:

Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis door Santanu Ghosh (16714626)

Onderwerpen:

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance door Marta J. Llorca-Cardenosa (14961612)

Onderwerpen:

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance door Marta J. Llorca-Cardenosa (14961612)

Onderwerpen:

Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis door Santanu Ghosh (16714626)

Onderwerpen:

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance door Marta J. Llorca-Cardenosa (14961612)

Onderwerpen:

Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis door Santanu Ghosh (16714626)

Onderwerpen:

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance door Marta J. Llorca-Cardenosa (14961612)

Onderwerpen:

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Table S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen:

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression door Chuandong Geng (17315310)

Onderwerpen: